Vir Biotechnology (NASDAQ:VIR) Issues Earnings Results

Vir Biotechnology (NASDAQ:VIR) posted its earnings results on Wednesday. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18, FiscalAI reports. The business had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.98 million. During the same period in the previous year, the firm earned ($1.17) earnings per share. The company’s revenue was down 178.3% compared to the same quarter last year.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta phase III results are approaching: Vir expects ECLIPSE 1 top-line data in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027. The trials assess its combination regimen in treatment-naïve patients, patients switching from bulevirtide, and a head-to-head comparison with bulevirtide; management believes the program could offer deep viral suppression and less frequent dosing.
• VIR-5500 advanced toward pivotal development: Astellas and Vir say the prostate cancer T-cell engager achieved proof of concept based on combined clinical, safety, pharmacology, and biomarker data, and the FDA granted it fast-track designation for late-line mCRPC. The companies aim to begin multiple phase III studies in 2027, though Vir did not disclose response durability or detailed trial plans.
• Gilead collaboration adds funding and validates Vir’s platform: Vir received $65 million upfront plus a $25 million equity investment at a 30% premium, and is eligible for $45 million in near-term preclinical milestones, up to $1.74 billion in additional milestones, and tiered royalties. Gilead will take responsibility for later development, manufacturing, and commercialization of candidates; milestone and royalty payments are contingent.
• Vir reported $901 million in cash, equivalents, and investments at quarter-end, excluding the $90 million Gilead payment received in October. Management expects its cash to fund operations into the second half of 2028, based on its current operating plan.
• VIR-5818’s data update has been pushed out: Following FDA feedback on the monotherapy arm, Vir plans to add backfill cohorts in a more homogeneous patient population to refine dose and schedule. The study remains ongoing and the data set is incomplete, although combination dose optimization continues.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $11.77 on Thursday. The stock’s 50 day moving average is $11.02 and its 200 day moving average is $9.56. The firm has a market cap of $1.99 billion, a P/E ratio of -6.33 and a beta of 1.70. Vir Biotechnology has a one year low of $4.82 and a one year high of $12.19.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir said it expects topline results from its ECLIPSE-1 hepatitis delta trial this quarter and highlighted additional oncology catalysts. The company also projects its cash runway into the second half of 2028, easing near-term financing concerns. Cash runway and ECLIPSE-1 update
• Positive Sentiment: Q3 loss narrowed to $0.57 per share, better than estimates of about $0.75–$0.80 and the $1.17 loss a year earlier. The earnings beat and improved year-over-year loss may support investor sentiment. Q3 results and corporate update
• Neutral Sentiment: EVP Vanina de Verneuil sold shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The sales were relatively small, and the stated purpose makes them a limited signal about management’s view of the business. Insider transaction details
• Negative Sentiment: Revenue was negative $0.19 million, below analysts’ $0.98 million estimate and down 178.3% year over year, tempering the earnings beat. Q3 earnings coverage

Insider Buying and Selling

In other Vir Biotechnology news, EVP Vanina de Verneuil sold 2,407 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total transaction of $26,717.70. Following the completion of the sale, the executive vice president owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. This represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

VIR has been the subject of several analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research lowered Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.